Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Fungal Infection Reports
Published in: Current Fungal Infection Reports 3/2013

01-09-2013 | Clinical Lab Issues (M Brandt, Section Editor)

Current Thoughts in Fungal Keratitis: Diagnosis and Treatment

Authors: Zubair Ansari, Darlene Miller, Anat Galor

Published in: Current Fungal Infection Reports | Issue 3/2013

Login to get access

Abstract

Fungal keratitis remains a challenging and often elusive diagnosis in geographic regions where it is endemic. Marred by delays in diagnosis, the sequelae of corneal fungal infections, though preventable, can be irreversible. Recent studies and advances in the arena have broadened the approach and treatment to mycotic keratitis. This review will discuss current diagnostic modalities of fungal keratitis and will particularly focus on treatment regimens. It will also explore future therapeutic models and critique the potential benefit of each.
Literature
1.
Wong TY, Ng TP, Fong KS, Tan DT. Risk factors and clinical outcomes between fungal and bacterial keratitis: a comparative study. CLAO J. 1997;23:275–81.PubMed
2.
• Sharma N, Chacko J, Velpandian T, et al. Comparative Evaluation of Topical versus Intrastromal Voriconazole as an Adjunct to Natamycin in Recalcitrant Fungal Keratitis. Ophthalmology 2012. Important trial that compared topical and intrastromal voriconazole in adjunct to natamycin. Showed no significant difference between topical and intrastromal voriconazole in best corrected visual acuity.
3.
Bharathi MJ, Ramakrishnan R, Meenakshi R, Padmavathy S, Shivakumar C, Srinivasan M. Microbial keratitis in South India: influence of risk factors, climate, and geographical variation. Ophthalmic Epidemiol. 2007;14:61–9.PubMedCrossRef
4.
Leck AK, Thomas PA, Hagan M, et al. Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis. Br J Ophthalmol. 2002;86:1211–5.PubMedCrossRef
5.
6.
7.
Tarabishy AB, Aldabagh B, Sun Y, et al. MyD88 regulation of Fusarium keratitis is dependent on TLR4 and IL-1R1 but not TLR2. J Immunol. 2008;181:593–600.PubMed
8.
Thomas PA, Kaliamurthy J. Mycotic keratitis: epidemiology, diagnosis and management. Clin Microbiol Infect. 2013;19:210–20.PubMedCrossRef
9.
Sun RL, Jones DB, Wilhelmus KR. Clinical characteristics and outcome of Candida keratitis. Am J Ophthalmol. 2007;143:1043–5.PubMedCrossRef
10.
Gower EW, Keay LJ, Oechsler RA, et al. Trends in fungal keratitis in the United States, 2001 to 2007. Ophthalmology. 2010;117:2263–7.PubMedCrossRef
11.
•• Gopinathan U, Garg P, Fernandes M, Sharma S, Athmanathan S, Rao GN. The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in South India. Cornea. 2002;21:555–9. This review presented the epidemiological features and laboratory results of the largest series of fungal keratitis ever reported in literature. Identified demographic features and risk factors that contributed to our knowledge of how FK is aquired.PubMedCrossRef
12.
Sirikul T, Prabriputaloong T, Smathivat A, Chuck RS, Vongthongsri A. Predisposing factors and etiologic diagnosis of ulcerative keratitis. Cornea. 2008;27:283–7.PubMedCrossRef
13.
Srinivasan M, Gonzales CA, George C, et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, south India. Br J Ophthalmol. 1997;81:965–71.PubMedCrossRef
14.
Foster CS. Fungal keratitis. Infect Dis Clin North Am. 1992;6:851–7.PubMed
15.
Pepose JS, Wilhelmus KR. Divergent approaches to the management of corneal ulcers. Am J Ophthalmol. 1992;114:630–2.PubMed
16.
Chin GN, Hyndiuk RA, Kwasny GP, Schultz RO. Keratomycosis in Wisconsin. Am J Ophthalmol. 1975;79:121–5.PubMed
17.
Doughman DJ, Leavenworth NM, Campbell RC, Lindstrom RL. Fungal keratitis at the University of Minnesota: 1971–1981. Trans Am Ophthalmol Soc. 1982;80:235–47.PubMed
18.
Jones DB, Sexton R, Rebell G. Mycotic keratitis in South Florida: a review of thirty-nine cases. Trans Ophthalmol Soc U K. 1970;89:781–97.PubMed
19.
Rosa Jr RH, Miller D, Alfonso EC. The changing spectrum of fungal keratitis in south Florida. Ophthalmology. 1994;101:1005–13.PubMed
20.
Bullock JD, Elder BL, Khamis HJ, Warwar RE. Effects of time, temperature, and storage container on the growth of Fusarium species: implications for the worldwide Fusarium keratitis epidemic of 2004–2006. Arch Ophthalmol. 2011;129:133–6.PubMedCrossRef
21.
Jones BR. Principles in the management of oculomycosis. XXXI Edward Jackson memorial lecture. Am J Ophthalmol. 1975;79:719–51.PubMed
22.
Dahlgren MA, Lingappan A, Wilhelmus KR. The clinical diagnosis of microbial keratitis. Am J Ophthalmol. 2007;143:940–4.PubMedCrossRef
23.
•• Prajna NV, Mascarenhas J, Krishnan T, et al. Comparison of natamycin and voriconazole for the treatment of fungal keratitis. Arch Ophthalmol. 2010;128:672–8. Important study that compared the use of natamycin and voriconazole in fungal keratitis, and to establish voriconazole as a worthy agent in FK.PubMedCrossRef
24.
McLeod SD, Kolahdouz-Isfahani A, Rostamian K, Flowers CW, Lee PP, McDonnell PJ. The role of smears, cultures, and antibiotic sensitivity testing in the management of suspected infectious keratitis. Ophthalmology. 1996;103:23–8.PubMed
25.
Zhang W, Yang H, Jiang L, Han L, Wang L. Use of potassium hydroxide, Giemsa and calcofluor white staining techniques in the microscopic evaluation of corneal scrapings for diagnosis of fungal keratitis. J Int Med Res. 2010;38:1961–7.PubMedCrossRef
26.
•• Sharma S, Kunimoto DY, Gopinathan U, Athmanathan S, Garg P, Rao GN. Evaluation of corneal scraping smear examination methods in the diagnosis of bacterial and fungal keratitis: a survey of eight years of laboratory experience. Cornea. 2002;21:643–7. Determined the sensitivity, specificity, and predictive values of Gram and potassium hydroxide with calcofluor white stains in the diagnosis of early and advanced microbial keratitis. Found that KOH prep with calcofluor white is a reliable lab test in the diagnosis of mycotic keratitis.PubMedCrossRef
27.
McGinnis M. Laboratory handbook of medical mycology. New York: Academic Press; 1980.
28.
Dursun D, Fernandez V, Miller D, Alfonso EC. Advanced Fusarium keratitis progressing to endophthalmitis. Cornea. 2003;22:300–3.PubMedCrossRef
29.
Keay LJ, Gower EW, Iovieno A, et al. Clinical and microbiological characteristics of fungal keratitis in the United States, 2001–2007: a multicenter study. Ophthalmology 2011.
30.
Ferrer C, Alio JL. Evaluation of molecular diagnosis in fungal keratitis. Ten years of experience. Journal of Ophthalmic Inflammation and Infection. 2011;1:15–22.PubMedCrossRef
31.
Erie JC, McLaren JW, Patel SV. Confocal microscopy in ophthalmology. Am J Ophthalmol. 2009;148:639–46.PubMedCrossRef
32.
• Vaddavalli PK, Garg P, Sharma S, Sangwan VS, Rao GN, Thomas R. Role of confocal microscopy in the diagnosis of fungal and acanthamoeba keratitis. Ophthalmology. 2011;118:29–35. Prospective, double masked study that evaluated the sensitivity, specificity, NPV and PPV of confocal microscopy. Proposed it as an accurate and reliable diagnostic modality in the diagnosis of fungal and Acanthamoeba keratitis.PubMedCrossRef
33.
Florcruz NV, Peczon I, Jr. Medical interventions for fungal keratitis. Cochrane database of systematic reviews 2008:CD004241.
34.
Yoon KC, Jeong IY, Im SK, Chae HJ, Yang SY. Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis. Cornea. 2007;26:814–8.PubMedCrossRef
35.
36.
Green WR, Bennett JE, Goos RD. Ocular penetration of amphotericin B: a report of laboratory studies and a case report of postsurgical cephalosporium endophthalmitis. Arch Ophthalmol. 1965;73:769–75.PubMedCrossRef
37.
Natamycin approved--first U.S. drug for fungal keratitis. FDA Drug Bull 1978;8:37–8.
38.
Medoff G, Kobayashi GS. Strategies in the treatment of systemic fungal infections. N Engl J Med. 1980;302:145–55.PubMedCrossRef
39.
Kalavathy CM, Parmar P, Kaliamurthy J, et al. Comparison of topical itraconazole 1 % with topical natamycin 5 % for the treatment of filamentous fungal keratitis. Cornea. 2005;24:449–52.PubMedCrossRef
40.
Tanure MA, Cohen EJ, Sudesh S, Rapuano CJ, Laibson PR. Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania. Cornea. 2000;19:307–12.PubMedCrossRef
41.
•• Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol. 2004;137:820–5. Experimental study that used a large microbiology database to investigate the susceptbility profile of the most common fungal pathogens in keratitis. First proposed the role of voriconazole in the therapeutic management of Candida and Aspergillus ocular infections.PubMedCrossRef
42.
Lalitha P, Shapiro BL, Srinivasan M, et al. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis. Arch Ophthalmol. 2007;125:789–93.PubMedCrossRef
43.
Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol. 2008;92:871–8.PubMedCrossRef
44.
Ramakrishnan T, Constantinou M, Jhanji V, Vajpayee RB. Factors affecting treatment outcomes with voriconazole in cases with fungal keratitis. Cornea. 2013;32:445–9.PubMedCrossRef
45.
Prajna NV, Nirmalan PK, Mahalakshmi R, Lalitha P, Srinivasan M. Concurrent use of 5 % natamycin and 2 % econazole for the management of fungal keratitis. Cornea. 2004;23:793–6.PubMedCrossRef
46.
Panda A, Sharma N, Angra SK. Topical fluconazole therapy of Candida keratitis. Cornea. 1996;15:373–5.PubMedCrossRef
47.
Rao SK, Madhavan HN, Rao G, Padmanabhan P. Fluconazole in filamentous fungal keratitis. Cornea. 1997;16:700.PubMedCrossRef
48.
Mahdy RA, Nada WM, Wageh MM. Topical amphotericin B and subconjunctival injection of fluconazole (combination therapy) versus topical amphotericin B (monotherapy) in treatment of keratomycosis. J Ocul Pharmacol Ther. 2010;26:281–5.PubMedCrossRef
49.
Sonego-Krone S, Sanchez-Di Martino D, Ayala-Lugo R, et al. Clinical results of topical fluconazole for the treatment of filamentous fungal keratitis. Graefes Arch Clin Exp Ophthalmol. 2006;244:782–7.PubMedCrossRef
50.
Fitzsimons R, Peters AL. Miconazole and ketoconazole as a satisfactory first-line treatment for keratomycosis. Am J Ophthalmol. 1986;101:605–8.PubMed
51.
Perez-Balbuena AL, Vanzzini-Rosano V, Valadez-Virgen Jde J, Campos-Moller X. Fusarium keratitis in Mexico. Cornea. 2009;28:626–30.PubMedCrossRef
52.
Anane S, Ben Ayed N, Malek I, et al. Keratomycosis in the area of Tunis: epidemiological data, diagnostic and therapeutic modalities. Ann Biol Clin (Paris). 2010;68:441–7.
53.
Mahdy RA, Nada WM, Wageh MM, Kader MA, Saleh MM, Alswad MM. Assessment safety and efficacy of a combination therapy of topical amphotericin B and subconjunctival fluconazole for the treatment of fungal keratitis. Cutan Ocul Toxicol. 2010;29:193–7.PubMedCrossRef
54.
Li L, Wang Z, Li R, Luo S, Sun X. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients. Am J Ophthalmol. 2008;146:724–8.PubMedCrossRef
55.
Xie L, Dong X, Shi W. Treatment of fungal keratitis by penetrating keratoplasty. Br J Ophthalmol. 2001;85:1070–4.PubMedCrossRef
56.
Sharma N, Agarwal P, Sinha R, Titiyal JS, Velpandian T, Vajpayee RB. Evaluation of intrastromal voriconazole injection in recalcitrant deep fungal keratitis: case series. Br J Ophthalmol 2011.
57.
Siatiri H, Daneshgar F, Siatiri N. Khodabande A. Cornea: The effects of intrastromal voriconazole injection and topical voriconazole in the treatment of recalcitrant Fusarium keratitis; 2011.
58.
Prakash G, Sharma N, Goel M, Titiyal JS, Vajpayee RB. Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis. Am J Ophthalmol. 2008;146:56–9.PubMedCrossRef
59.
Wei LC, Tsai TC, Tsai HY, Wang CY, Shen YC. Comparison of voriconazole concentration in the aqueous humor and vitreous between non-scraped and scraped corneal epithelium groups after topical 1 % voriconazole application. Curr Eye Res. 2010;35:573–9.PubMedCrossRef
60.
•• Xie L, Zhai H, Shi W. Penetrating keratoplasty for corneal perforations in fungal keratitis. Cornea. 2007;26:158–62. Retrospective study that determined penetrating keratoplasty (PKP) an effective surgical treatment of antifungal refractory mycotic keratitis.PubMedCrossRef
61.
Garg P, Gopinathan U, Nutheti R, Rao GN. Clinical experience with N-butyl cyanoacrylate tissue adhesive in fungal keratitis. Cornea. 2003;22:405–8.PubMedCrossRef
62.
Tseng SC. Amniotic membrane transplantation for ocular surface reconstruction. Biosci Rep. 2001;21:481–9.PubMedCrossRef
63.
Chen HC, Tan HY, Hsiao CH, Huang SC, Lin KK, Ma DH. Amniotic membrane transplantation for persistent corneal ulcers and perforations in acute fungal keratitis. Cornea. 2006;25:564–72.PubMedCrossRef
64.
Bell NP, Karp CL, Alfonso EC, Schiffman J, Miller D. Effects of methylprednisolone and cyclosporine A on fungal growth in vitro. Cornea. 1999;18:306–13.PubMedCrossRef
65.
Price Jr FW, Price MO. Descemet's stripping with endothelial keratoplasty in 50 eyes: a refractive neutral corneal transplant. J Refract Surg. 2005;21:339–45.PubMed
66.
Reddy JC, Hammersmith KM, Nagra PK, Rapuano CJ. The role of penetrating keratoplasty in the era of selective lamellar keratoplasty. Int Ophthalmol Clin. 2013;53:91–101.PubMedCrossRef
67.
Qu LJ, Xie LX. Changing indications for lamellar keratoplasty in Shandong, 1993–2008. Chin Med J (Engl). 2010;123:3268–71.
68.
•• Xie L, Shi W, Liu Z, Li S. Lamellar keratoplasty for the treatment of fungal keratitis. Cornea. 2002;21:33–7. These studies evaluated lamellar keratoplasty as an effective surgical intervention in the setting of antifungal refractory FK.PubMedCrossRef
69.
Xie L, Zhong W, Shi W, Sun S. Spectrum of fungal keratitis in north China. Ophthalmology. 2006;113:1943–8.PubMedCrossRef
70.
Hu JZ, Xie LX. Clinical study on the recurrence of fungal keratitis after lamellar keratoplasty. [Zhonghua yan ke za zhi]. Chinese Journal of Ophthalmology. 2008;44:111–5.PubMed
71.
Anshu A, Parthasarathy A, Mehta JS, Htoon HM, Tan DT. Outcomes of therapeutic deep lamellar keratoplasty and penetrating keratoplasty for advanced infectious keratitis: a comparative study. Ophthalmology. 2009;116:615–23.PubMedCrossRef
72.
Xie L, Zhai H, Zhao J, Sun S, Shi W, Dong X. Antifungal susceptibility for common pathogens of fungal keratitis in Shandong Province, China. Am J Ophthalmol. 2008;146:260–5.PubMedCrossRef
73.
Khairallah SH, Byrne KA, Tabbara KF. Fungal keratitis in Saudi Arabia. Doc Ophthalmol. 1992;79:269–76.PubMedCrossRef
74.
Bhartiya P, Daniell M, Constantinou M, Islam FM, Taylor HR. Fungal keratitis in Melbourne. Clin Experiment Ophthalmol. 2007;35:124–30.PubMed
75.
Sponsel WE, Graybill JR, Nevarez HL, Dang D. Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol. 2002;86:829–30.PubMedCrossRef
76.
Tu EY, McCartney DL, Beatty RF, Springer KL, Levy J, Edward D. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol. 2007;143:222–7.PubMedCrossRef
Metadata
Title
Current Thoughts in Fungal Keratitis: Diagnosis and Treatment
Authors
Zubair Ansari
Darlene Miller
Anat Galor
Publication date
01-09-2013
Publisher
Springer US
Published in
Current Fungal Infection Reports / Issue 3/2013
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-013-0150-1

Other articles of this Issue 3/2013

Current Fungal Infection Reports 3/2013 Go to the issue

Invited Commentary

Report From the 39th Annual Meeting of the European Group for Blood and Marrow Transplantation, London, 7–10 April 2013

Clinical Lab Issues (M Brandt, Section Editor)

Coelomycete Fungi in the Clinical Lab

CLINICAL LAB ISSUES (M BRANDT, SECTION EDITOR)

The Mammalian Pathogenic Oomycetes

Clinical Lab Issues (M Brandt, Section Editor)

Filamentous Basidiomycetes in the Clinical Laboratory

Advances in Diagnosis of Invasive Fungal Infections (U Binder, Section Editor)

Genomics and Proteomics as Compared to Conventional Phenotypic Approaches for the Identification of the Agents of Invasive Fungal Infections

Advances in Diagnosis of Invasive Fungal Infections (U Binder, Section Editor)

Lateral-Flow Device for Diagnosis of Fungal Infection
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits